Download MendeleyDiscovery of Potent, Selective, and Orally Available IRE1 alpha Inhibitors Demonstrating Comparable PD Modulation to IRE1 Knockdown in a Multiple Myeloma Model.
Braun, M.G., Ashkenazi, A., Beveridge, R.E., Castanedo, G., Wallweber, H.A., Beresini, M.H., Clark, K.R., De Bruyn, T., Fu, L., Gibbons, P., Jiang, F., Kaufman, S., Kan, D., Kiefer, J.R., Leclerc, J.P., Lemire, A., Ly, C., Segal, E., Sims, J., Wang, W., Wei, W., Zhao, L., Schwarz, J.B., Rudolph, J.(2024) J Med Chem 67: 8708-8729
- PubMed: 38748820
- DOI: https://doi.org/10.1021/acs.jmedchem.3c02425
- Primary Citation of Related Structures:
8UVL - PubMed Abstract:
The lack of selective and safe in vivo IRE1α tool molecules has limited the evaluation of IRE1α as a viable target to treat multiple myeloma. Focus on improving the physicochemical properties of a literature compound by decreasing lipophilicity, molecular weight, and basicity allowed the discovery of a novel series with a favorable in vitro safety profile and good oral exposure. These efforts culminated in the identification of a potent and selective in vivo tool compound, G-5758 , that was well tolerated following multiday oral administration of doses up to 500 mg/kg. G-5758 demonstrated comparable pharmacodynamic effects to induced IRE1 knockdown as measured by XBP1s levels in a multiple myeloma model (KMS-11).
Organizational Affiliation:
Genentech, Inc., 1 DNA Way, South San Francisco, California 94080, United States.
